10:23 AM EST, 02/18/2025 (MT Newswires) -- Longeveron ( LGVN ) said Tuesday that the World Health Organization approved laromestrocel for the non-proprietary name of the company's Lomecel-B cellular therapy.

The US Food and Drug Administration granted Lomecel-B regenerative medicine advanced therapy designation and fast track designation to treat mild Alzheimer's disease, and orphan drug designation, fast track designation, and rare pediatric disease designation to treat hypoplastic left heart syndrome, or HLHS.

HLHS is a rare pediatric disease.

Longeveron ( LGVN ) shares were down 5.6% in recent trading.

Price: 1.58, Change: -0.09, Percent Change: -5.57